10X Genomics Inc (TXG) — Capital Reinvestment Ratio

Latest as of June 2026: 0.09x

10X Genomics Inc (TXG) has a Capital Reinvestment Ratio of 0.09x as of June 2026, meaning it reinvests 0% of its operating cash flow ($16.97 Million) in capital expenditures ($1.59 Million). Check 10X Genomics Inc tangible net worth ratio to evaluate the tangible quality of the company's equity base.

Capital Reinvestment Ratio

0.09x
Capex / Operating Cash Flow

Operating Cash Flow

$16.97 Million
USD

Capital Expenditures

$1.59 Million
USD

Data as of

Jun 2026
Most recent filing

10X Genomics Inc Capital Reinvestment Ratio (2019–2025)

This chart tracks 10X Genomics Inc's Capital Reinvestment Ratio across 3 annual periods. For the full cash flow conversion analysis, see 10X Genomics Inc operating cash flow efficiency.

Annual Capital Reinvestment Ratio for 10X Genomics Inc (2019–2025)

Year-by-year Capital Reinvestment Ratio for 10X Genomics Inc from 2019 to 2025. See free cash flow generation of 10X Genomics Inc to measure how efficiently the company converts operating cash flow to free cash.

Year Reinvestment Ratio Operating CF (USD) Capital Expenditures YoY Change
2025 0.04x $136.05 Million $5.93 Million ▼ -97.7%
2024 1.86x $6.66 Million $12.39 Million ▲ +50.6%
2019 1.24x $34.63 Million $42.77 Million
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow